CSL Ltd Annual Report 2021

Outstanding share-based payment equity instruments The number and weighted average exercise price for each share-based payment scheme outstanding is as follows. All schemes are settled by physical delivery of shares except for instruments that may be settled in cash at the discretion of the Board. Options Performance Rights Number Weighted average exercise price Number Weighted average exercise price Outstanding at the beginning of the year 308,186 A$105.63 211,364 A$0.00 Granted during year 0 A$0.00 0 A$0.00 Exercised during year (308,186) A$105.63 (197,646) A$0.00 Cash settled during year 0 A$0.00 (1,813) A$0.00 Forfeited during year 0 A$0.00 (3,555) A$0.00 GESP true-up 0 A$0.00 0 A$0.00 Closing balance at the end of the year 0 A$0.00 8,350 A$0.00 Exercisable at the end of the year 0 A$0.00 8,350 A$0.00 The share price at the dates of exercise (expressed as a weighted average) by equity instrument type, is as follows: 2021 2020 Options A$290.64 A$243.87 Performance Rights A$290.92 A$243.73 RGP A$280.98 A$248.01 EPA A$281.68 A$239.85 GESP A$263.25 A$276.35 (b) Key Management Personnel Disclosures The remuneration of key management personnel is disclosed in section 18 of the Directors’ Report and has been audited. Total compensation for key management personnel 2021 US$ 2020 US$ Total of short term remuneration elements 9,280,941 11,389,819 Total of post employment elements 142,694 146,836 Total of other long term elements 26,173 37,510 Total share-based payments 11,751,250 13,915,267 Total of all remuneration elements 21,201,058 25,489,432 CSL Limited Annual Report 2020/21 120 Notes to the Financial Statements